



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 13 Nov 2017 (#41)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

**Confirm your intent to apply ASAP, but not later than 30 days before the submission date.**

Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)

## Important Notices:

- Notice of Extension of the Response Date for NOT-LM-17-006 " Request for Information (RFI): Next-Generation Data Science Challenges in Health and Biomedicine" ([NOT-LM-18-001](#))
- Request for Information on Developing Experimental Design "Emoji" Symbols for Use in Scientific Presentations ([NOT-NS-18-014](#))

### 1. Systems Biology Approaches using Non-Mammalian Laboratory Animals to Uncover Causes of Neurodegeneration that Might Underlie Alzheimers Disease and Related Dementias (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** ([RFA-AG-18-021](#))

**Type:** R01

**Application Due Date:** February 21, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The National Institute on Aging is seeking applications on systems biology approaches using non-mammalian laboratory animal models to increase our understanding of the basic biology underpinning neurodegeneration. It is expected that research supported under this FOA will provide new insights into molecular networks that might be involved in causing, amplifying or protecting against neurodegeneration, and that, in turn, might ultimately contribute to Alzheimer's disease or related dementias. Importantly, a major goal of this FOA is to use interaction and regulatory networks produced and analyzed using systems biology to gain these new insights. Because this FOA is directed toward discovery, currently employed genetically modified laboratory animals used to study AD are not required, although they may be used. Because this FOA requires systems biology approaches, data used to build interaction or regulatory networks may also come from humans or other mammals in which AD, related dementias, or aging-related cognitive decline have been observed. This FOA will only support studies using non-mammalian laboratory animal models; studies involving humans or experiments with mammals will not be allowed under this FOA.

**Budget:** NIA intends to commit \$3.3 million in FY 2018 to fund 4-5 awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 2. NIH Blue Print: Development and Validation of Technologies for Rapid Isolation and Characterization of Extracellular Vesicles of Central Nervous System Origin (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** ([RFA-MH-18-600](#))

**Type:** R21/R33

**Application Due Date:** January 22, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages applications that will develop novel technologies and/or tools for the isolation and characterization of extracellular vesicles (EVs) of Central Nervous System (CNS) origin. The primary focus of the technology development includes robust and reproducible CNS-EV isolation methods. Specifically, there is a need to establish technologies for the isolation and purification of CNS-EVs from peripheral samples and the characterization of CNS-EV types, cargos, and origin, as well as to validate these methods for further analyses. Validation of these technologies may include the analysis of the full range of EV composition such as RNA, proteins, lipids, and metabolites.

**Budget:** The NIH Blueprint intends to commit \$2M in FY 2018 to fund approximately 6 awards. However, the total amount awarded and the number of awards made will depend upon the number, quality, and cost of the applications received. For the R21 phase, the combined budget for direct costs for a two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. For the R33 phase, application budgets may not exceed \$500,000 in annual direct costs. The duration of the entire R21/R33 award may not exceed 5 years. The R21 phase may not exceed 2 years of support. The R33 phase may not exceed 3 years of support.

### 3. BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-MH-18-510\)](#)

**Type:** F32

**Application Due Date:** March 15, 2018; December 7, 2018; August 7, 2019; April 7, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of the BRAIN Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

**Budget:** The BRAIN Initiative intends to commit \$1.3M per year in fiscal years 2018-2020 to fund an estimate of 20 awards per year. Award budgets are composed of stipends, tuition and fees, and institutional allowance, as described below. Individuals may receive up to 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from institutional training grants (e.g., T32) and an individual fellowship award. Kirschstein-NRSA awards provide stipends as a subsistence allowance to help defray living expenses during the research and clinical training experiences. NIH will contribute to the combined cost of tuition and fees at the rate in place at the time of award. The application should request a Kirschstein-NRSA institutional allowance to help defray the cost of fellowship expenses such as health insurance, research supplies, equipment, books, and travel to scientific meetings. In addition to the standard institutional allowance, the application may request up to \$5,000 annually to defray the cost of participation in meetings including annual BRAIN Initiative meetings. NIH does not separately reimburse indirect costs (also known as Facilities & Administrative [F&A] Costs) for fellowships. Costs for administering fellowships are part of Institutional Allowance. Stipend levels, as well as funding amounts for tuition and fees and the institutional allowance are announced annually in the NIH Guide for Grants and Contracts, and are also posted on the Ruth L. Kirschstein National Research Service Award (NRSA)

### 4. Altered neuronal circuits, receptors and networks in HIV-induced Central Nervous System dysfunction -Clinical Trial Not Allowed

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-MH-18-610\)](#)  
[\(RFA-MH-18-611\)](#)

**Type:** R01  
R21

**Application Due Date:** January 8, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites research grant applications to decipher pathways and mechanisms responsible for HIV-1 induced central nervous system (CNS) dysfunction seen in virally suppressed HIV-1 positive patients, by understanding the causal role played by altered neuronal circuits, neuronal receptors and neuronal networks. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. RFA [RFA-MH-18-610] uses the R01 grant mechanism while the companion RFA [RFA-MH-18-611] uses the R21 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 [RFA-MH-18-611] mechanism, while applicants with preliminary data and a discrete, specified, circumscribed project can apply using the R01 [RFA-MH-18-610] mechanism.

**Budget:** NIMH intends to commit an estimate of \$2,000,000; NINDS intends to commit approximately \$1,500,000; NIDA intends to commit an estimate of \$2,000,000; NIAAA intends to commit an estimate of \$1,000,000 in FY 2018 to fund 3-5 awards in response to this FOA and the companion R21 FOA. Future year amounts will depend on annual appropriations. **R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

### 5. Translational Neural Devices (Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-NS-18-011\)](#)

**Type:** UG3/UH3

**Application Due Date:** February 21, 2018, June 21, 2018, October 22, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical trial to collect safety and effectiveness data required to support a marketing application or to inform final device design.

**Budget:** NINDS intends to commit \$4,000,000 to support 3-5 awards per fiscal year. Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants should rarely exceed \$1,000,000 direct costs per year for the UG3 phase and \$1,500,000 direct costs per year for the UH3 phase. The proposed project period for the UG3 phase must not exceed 4 years. The proposed project period for the UH3 phase must not exceed 4 years. The total duration of the UG3 and UH3 may not exceed 5 years.

## 6. The Health of Sexual and Gender Minority (SGM) Populations (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-037\)](#)  
[\(PA-18-040\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.

**Budget: R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R03:** Direct costs are limited to \$100,000 direct costs over the 2-year period, with no more than \$50,000 in direct costs allowed in a single year.

## 7. Multidisciplinary Research in Vulvodynia (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-089\)](#)  
[\(PA-18-096\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to indicate a continued interest in the topic area of vulvodynia or chronic vulvar pain of unknown etiology as an integral area of branch research. This announcement is intended to encourage new research applications in the exploration of etiology, prevention, diagnosis, and therapeutics in the field of vulvodynia. Applications utilizing multidisciplinary approaches and interdisciplinary investigative teams are of particular interest to advance this research agenda.

**Budget: R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period is limited to 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

## 8. End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-137\)](#)  
[\(PA-18-155\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

**Budget: R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

## 9. Personalized Strategies to Manage Symptoms of Chronic Illness (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-138\)](#)  
[\(PA-18-156\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

## 10. Innovative Questions in Symptom Science and Genomics (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-139\)](#)  
[\(PA-18-157\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

### 11. Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-140\)](#)  
[\(PA-18-158\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement is to encourage applications on biomarker discovery that utilize metabolomics approaches to advance the understanding, assessment and management of symptoms.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

### 12. Mechanisms, Models, Measurement, and Management in Pain Research (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-141\)](#)  
[\(PA-18-159\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

### 13. Environmental Exposures and Health: Exploration of Non-Traditional Settings (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-142\)](#)  
[\(PA-18-160\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to encourage interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities across the lifespan for those living or spending time in non-traditional settings (i.e. playgrounds and nursing homes). These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms, and other health conditions/diseases; including low respiratory disease, chronic obstructive pulmonary disease, cardiovascular disease, and complex environmental exposures that may be exacerbated by non-chemical stressors encountered in community settings, physiological function of organs and systems of the fetus/child/adolescence, and lower respiratory disease. Risk identification and symptom management include prevention and behavior changes and actions to maintain health and prevent disease with an emphasis on the individual, family, and community which will advance nursing science. For purposes of this FOA, non-traditional settings include, but are not limited to, places such as community centers; pre-school and non-traditional school environments (e.g., churches, daycare, home-based schools, dormitories, alternative schools, and playgrounds); child and older adult foster care facilities; older adult day care facilities; half-way homes; and assisted living and long-term care facilities.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

### 14. Symptom Management in HIV-Infected Individuals with Comorbid Conditions (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-143\)](#)  
[\(PA-18-161\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The FOA invites research applications focused on developing, adapting and testing innovative cost-effective strategies to prevent, identify and manage symptoms of HIV-associated Non-AIDS conditions (HANA) and other comorbidities among older adults with prolonged HIV infection.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

### 15. Metabolic Contributions to the Neurocognitive Complications of Diabetes: Ancillary Studies (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-051\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites applications for human studies to elucidate the etiology and pathogenesis of the increased risk for neurocognitive impairment associated with type 2 diabetes.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 16. Health Promotion Among Racial and Ethnic Minority Males (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-144\)](#)  
[\(PA-18-162\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This initiative seeks applications that propose to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: 1) enhance our understanding of the numerous factors (e.g., socio demographic, community, societal, personal) influencing the health promoting behaviors of racial and ethnic minority males across the life cycle, and 2) encourage applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males age 18 and older.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

### 17. Use of Technology to Enhance Patient Outcomes and Prevent Illness (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-145\)](#)  
[\(PA-18-163\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) seeks clinical research focused on the development and utilization of technologies that can help address patient outcomes. Relevant areas of technology include remote healthcare delivery to patients via telehealth, robotics to enhance medication adherence, on-site (e.g., clinical or home setting) care delivery, mobile health to increase access and adherence, web-based decision support tools, and others. Research projects may focus on assessment, diagnosis, intervention development, or intervention implementation. Research projects that a) incorporate emerging and cutting edge technologies to explain and predict patient trajectories, b) inform interventions, c) support real-time clinical decision making, and d) facilitate effective long-term management of chronic illness are especially needed. Critical to this FOA, proposed research should identify specific patient outcomes expected to improve from technological approaches. The specific tools or interventions proposed should clearly indicate how they will enhance patient benefits in environments, such as clinical settings, and/or in the home and community.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

### 18. Self-Management Interventions and Technologies to Sustain Health and Optimize Functional Capabilities (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-146\)](#)  
[\(PA-18-164\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) seeks clinical research on self-management interventions and technologies that improve health and quality of life in persons needing assistance to optimize and maintain existing functional capabilities, prevent/delay disabilities and navigate their environment. The research focus encompasses maintenance/restorative care that can be tailored to individuals' existing functional abilities and interests and is intended to enhance physical, sensory, motor, and mental capabilities. Of particular interest is research designed to maintain functional capabilities in such conditions as cardiac and respiratory insufficiency, movement impairment associated with arthritis, chronic back pain, stroke, and other physical or cognitive disabilities.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

### 19. Addressing Unmet Needs in Persons with Dementia to Decrease Behavioral Symptoms and Improve Quality of Life (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-147\)](#)  
[\(PA-18-165\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research addressing behavioral and psychological symptoms of dementia (BPSD) and the association of BPSD with unmet physical, social, or environmental needs in persons with dementia.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

## 20. Improving Individual and Family Outcomes through Continuity and Coordination of Care in Hospice (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-148\)](#)  
[\(PA-18-166\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) seeks to stimulate research that focuses on reducing negative individual and family outcomes related to unwanted transitions at the end of life and optimizing the individual and family outcomes related to high quality coordination of care of care of individuals who are enrolled in hospice. This FOA emphasizes individuals who are receiving hospice care and their family caregivers, in any setting where hospice care is provided, including their home, a relative's home, a hospice inpatient facility, an assisted living facility, a short- or long-term care facility, or a hospital.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

## 21. Palliative Care Needs of Individuals with Advanced Rare Diseases and Their Family Caregivers (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-149\)](#)  
[\(PA-18-167\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

## 22. Promoting Caregiver Health Using Self-Management (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-150\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this initiative is to stimulate research in promoting caregiver health using self-management. Caregiving is an important science area since the number of people living longer with chronic conditions is growing. Informal caregivers (lay caregivers) are defined as unpaid individuals (spouses, partners, family members, friends, or neighbors) involved in assisting others with activities of daily living and/or medical tasks. Formal caregivers are paid, delivering care in one's home or care settings (daycare, residential care facility). This concept focuses on informal caregivers.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 23. Chronic Condition Self-Management in Children and Adolescents (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-151\)](#)  
[\(PA-18-168\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to improve self-management and quality of life in children and adolescents with chronic conditions. Managing a chronic condition is an unremitting responsibility for children and their families. Children with a chronic condition and their families have a long-term responsibility for self-management. This FOA encourages research that takes into consideration various factors that influence self-management such as individual differences, biological and psychological factors, family/caregivers and sociocultural context, family-community dynamics, healthcare system factors, technological advances, and the role of the environment.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

## 24. Reducing Health Disparities Among Minority and Underserved Children (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-152\)](#)  
[\(PA-18-169\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This initiative encourages research that targets the reduction of health disparities among children. Investing in early childhood development is essential. Specific targeted areas of research include bio-behavioral studies that incorporate multiple factors that influence child health disparities such as biological (e.g., genetics, cellular, organ systems), lifestyle factors, environmental (e.g., physical and family environments) social (e.g., peers), economic, institutional, and cultural and family influences; studies that target the specific health promotion needs of children with a known health condition and/or disability; and studies that test, evaluate, translate, and disseminate health promotion prevention and interventions conducted in traditional and non-traditional settings.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000.No more than \$200,000 may be requested in any single year.

## 25. Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-192\)](#)

**Type:** R01

[\(PA-18-197\)](#)

R21

[\(PA-18-198\)](#)

R03

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The objective of this Funding Opportunity Announcement (FOA) is to encourage applications that use human laboratory paradigms and/or clinical trials to evaluate the safety and efficacy of novel or re-purposed compounds, that bind to new targets, for treatment of alcohol use disorder (AUD) or AUD with a comorbid post-traumatic stress disorder.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R03:** The combined budget for direct costs for the two year project period may not exceed \$100,000. No more than \$50,000 in direct costs may be requested in any single year.

## 26. Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-193\)](#)

**Type:** R01

[\(PA-18-199\)](#)

R21

[\(PA-18-200\)](#)

R03

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The objective of this Funding Opportunity Announcement (FOA) is to encourage research on screening and brief interventions to prevent and/or reduce alcohol use and alcohol-related harms among underage and young adult populations.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R03:** The combined budget for direct costs for the two year project period may not exceed \$100,000. No more than \$50,000 in direct costs may be requested in any single year.

## 27. Alcohol Use Disorders: Behavioral Treatment, Services and Recovery Research (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-194\)](#)

**Type:** R01

[\(PA-18-202\)](#)

R21

[\(PA-18-201\)](#)

R03

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages grant applications from institutions/organizations that propose to support research on behavioral treatment for alcohol use disorders; organizational, financial, and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; and phenomenon of recovery from alcohol use disorders.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R03:** The combined budget for direct costs for the two year project period may not exceed \$100,000. No more than \$50,000 in direct costs may be requested in any single year.

## 28. National Institute of Mental Health NIMH Exploratory/Developmental Research Grant (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-350\)](#)

**Type:** R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.

**Budget:** Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year.

## 29. Bioengineering Research Grants (BRG) (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-206\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years, depending on the policy of each NIH Institute.

### 30. Human Subjects Mechanistic and Minimal Risk Studies (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-351\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this FOA is to encourage applications that seek to conduct studies of the visual system. This FOA will support applications that either

- Those that involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or
- Those that are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects.

A mechanistic trial is defined as "A study designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. "Minimal risk" means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.

NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA. Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 31. Early Phase Clinical Trials in Imaging and Image-Guided Interventions (Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-011\)](#)

**Type:** R01

**Application Due Date:** February 14, 2018, June 28, 2018; October 11, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPoREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

**Budget:** Application budget should reflect the actual needs of the proposed project and is limited to \$500,000 in direct costs for the total project period. No more than \$250,000 in direct costs may be requested in any single year. The total project period may not exceed 3 years.

### 32. Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-091\)](#)

**Type:** R01

[\(PAR-18-094\)](#)

R21

[\(PAR-18-095\)](#)

R03

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more basic, exploratory and longitudinal research. Possible topics of study include, but are not limited to, the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study designs ranging from basic science and animal models through prospective randomized controlled trials. It is hoped that as a result of research supported through this funding opportunity, outcomes will improve both in terms of the prevention and treatment of MODS in children.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year. **R03:** Application budgets are limited to \$50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

### 33. Bioengineering Research Partnerships (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-208\)](#)

**Type:** U01

**Application Due Date:** May 8, 2018, September 13, 2018 and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.



### 34. Selected Topics in Transfusion Medicine (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-126\)](#)  
[\(PAR-18-132\)](#)

**Type:** R01  
R21

**Application Due Date:** R01: February 5, 2018; October 5, 2018; February 5, 2019; October 5, 2019 R21: February 16, 2018; October 16, 2018; February 16, 2019; October 16, 2019 **Aids Dates:** May 7, 2018; January 7, 2019; May 7, 2019; January 7, 2020 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages research grant applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Research focused on improving blood donor health, the safety and availability of blood products, and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how best to minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing the risks associated with the donation process and developing enhanced recruitment and retention programs.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21: Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year.

### 35. Alzheimer's Drug-Development Program (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-174\)](#)

**Type:** U01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies or, discovery activities such as high throughput screening and hit optimization.

**Budget:** Application budgets are limited to \$1,000,000 in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. For Early Stage projects, the project period is limited to five years. For Late Stage projects, the project period is limited to three years.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: [Dr Christa Coetsee](#) • Tel: 9838 • Email: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)